Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 471

Next Previous
Drug Profile

CTX 471

Alternative Names: CTX-471

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab
  • Developer Compass Therapeutics; Merck & Co
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Aug 2025 Compass Therapeutics plans a phase II trial in Solid tumours in in the second half of 2025 (IV, Infusion)
  • 21 May 2025 Compass Therapeutics completes a phase-I trial in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT03881488)
  • 28 Apr 2025 CTX 471 is covered by patent protection in USA, Taiwan, China, Eurasia, Japan, Korea, Malaysia, Singapore, and New Zealand

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top